CN1289080C - 替代雌激素的太太天雌素及其应用 - Google Patents
替代雌激素的太太天雌素及其应用 Download PDFInfo
- Publication number
- CN1289080C CN1289080C CN 200410072706 CN200410072706A CN1289080C CN 1289080 C CN1289080 C CN 1289080C CN 200410072706 CN200410072706 CN 200410072706 CN 200410072706 A CN200410072706 A CN 200410072706A CN 1289080 C CN1289080 C CN 1289080C
- Authority
- CN
- China
- Prior art keywords
- estrogen
- isoflavone
- analogy
- composition
- estrogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940011871 estrogen Drugs 0.000 title claims abstract description 83
- 239000000262 estrogen Substances 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 235000013311 vegetables Nutrition 0.000 title claims abstract description 26
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 29
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 29
- 230000001076 estrogenic effect Effects 0.000 claims abstract description 25
- 229930012930 isoflavone derivative Natural products 0.000 claims abstract description 13
- 150000002515 isoflavone derivatives Chemical class 0.000 claims abstract description 13
- 241000411851 herbal medicine Species 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 claims description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 15
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 11
- 235000006539 genistein Nutrition 0.000 claims description 11
- 229940045109 genistein Drugs 0.000 claims description 11
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 244000068988 Glycine max Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- RJKLDOLOCIQYFS-PRTISISMSA-N miroestrol Chemical compound C12=COC3=CC(O)=CC=C3[C@H]2C(C)(C)[C@@H]2[C@@H]([C@H]3O)[C@@]1(O)C(=O)C[C@]3(O)C2 RJKLDOLOCIQYFS-PRTISISMSA-N 0.000 claims description 4
- CKEZIBBDMDFHQQ-ILKNQKGPSA-N miroestrol Natural products CC1(C)[C@H]2C[C@]3(O)CC(=O)[C@H]([C@@H]2[C@H]3O)C4=COc5ccccc5[C@@H]14 CKEZIBBDMDFHQQ-ILKNQKGPSA-N 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 201000010251 cutis laxa Diseases 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 230000037182 bone density Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 7
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 6
- 201000010881 cervical cancer Diseases 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 description 29
- 239000011575 calcium Substances 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 15
- 150000001299 aldehydes Chemical class 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000029078 coronary artery disease Diseases 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 102000004067 Osteocalcin Human genes 0.000 description 6
- 108090000573 Osteocalcin Proteins 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229930003944 flavone Natural products 0.000 description 6
- 235000011949 flavones Nutrition 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 5
- 229960000452 diethylstilbestrol Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 210000000963 osteoblast Anatomy 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 208000000501 Lipidoses Diseases 0.000 description 3
- 206010024585 Lipidosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004097 bone metabolism Effects 0.000 description 3
- 150000001669 calcium Chemical class 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- RTRZOHKLISMNRD-UHFFFAOYSA-N isoflavanone Chemical compound C1OC2=CC=CC=C2C(=O)C1C1=CC=CC=C1 RTRZOHKLISMNRD-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 2
- 229940052490 naringin Drugs 0.000 description 2
- 229930019673 naringin Natural products 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- PBQVHWFDMNCCIH-KNJAVFAGSA-N (4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C([C@H]1C(N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC PBQVHWFDMNCCIH-KNJAVFAGSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000594558 Labium Species 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010031299 Osteosis Diseases 0.000 description 1
- 206010033122 Ovarian atrophy Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 231100001043 ovarian atrophy Toxicity 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 动物数(只) | 4个月 | 7个月 | ||
BMC(g) | BMD(mg/cm3) | BMC(g) | BMD(mg/cm3) | |||
假手术去卵巢E3TIP | --1.0100 | 10101010 | 5.32±0.514.90±0.29△5.32±0.40*5.62±0.77* | 0.278±0.0140.249±0.016△△0.270±0.022*0.279±0.026* | 5.68±0.455.37±0.245.21±0.375.83±0.52* | 0.281±0.0170.256±0.008△△0.269±0.016*0.293±0.016* |
检测项目 | A | B | C | D |
骨钙含量(%) | 21.08±1.32* | 20.62±0.88* | 20.53±0.91 | 18.30±0.76 |
骨磷含量(%) | 22.15±0.85 | 21.26±1.33 | 21.71±0.92 | 21.93±0.91 |
骨矿物质含量(%) | 61.78±1.14* | 61.47±1.36* | 58.98±1.36 | 56.10±1.27 |
骨密度(mg/cm3) | 1.33±0.08 | 1.38±0.107 | 1.28±0.08 | 1.29±0.07 |
组别 | 骨钙素(ng/mg) | AKP(金氏单位/100ml) | TRACP(u/L) | E2(pg/ml) |
A | 2.317±0.931 | 13.82±2.98 | 1.938±1.737* | 212.00±17.99* |
B | 2.233±1.340 | 12.28±1.47 | 5.855±3.848 | 201.71±107.61* |
C | 2.110±0.708 | 12.63±3.18 | 4.950±1.750 | 234.38±168.13* |
D | 2.627±0.879 | 14.43±2.24 | 4.564±3.235 | 170.86±36.99 |
组 | E2 | Ca | Dpd/Cr | BGP |
别 | (pg/ml) | (mg/dl) | (nmol/mmol) | (ng/ml) |
A | 7.50±1.45**** | 8.35±1.08** | 18.1±3.7** | 42.75±3.87** |
B | 1.08±0.38 | 11.36±1.39 | 28.0±3.0 | 31.4±4.33 |
C | 4.77±1.31**** | 8.23±1.11** | 13.6±2.5*** | 50.84±4.28**** |
D | 3.37±0.99**** | 8.41±1.06** | 10.6±4.0**** | 51.99±6.37**** |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410072706 CN1289080C (zh) | 2004-11-11 | 2004-11-11 | 替代雌激素的太太天雌素及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410072706 CN1289080C (zh) | 2004-11-11 | 2004-11-11 | 替代雌激素的太太天雌素及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634354A CN1634354A (zh) | 2005-07-06 |
CN1289080C true CN1289080C (zh) | 2006-12-13 |
Family
ID=34846782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410072706 Expired - Fee Related CN1289080C (zh) | 2004-11-11 | 2004-11-11 | 替代雌激素的太太天雌素及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1289080C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102905714A (zh) * | 2010-03-31 | 2013-01-30 | 株式会社爱茉莉太平洋 | 含有香豆雌酚或包含香豆雌酚的豆提取物的组合物 |
CN105961926A (zh) * | 2016-07-14 | 2016-09-28 | 湖南湘湖水产有限公司 | 种鳖复壮配合饲料 |
-
2004
- 2004-11-11 CN CN 200410072706 patent/CN1289080C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1634354A (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101288686B (zh) | 一种增加骨密度的保健制剂及制备方法 | |
CN1899342A (zh) | 一种治疗糖尿病的口服药物及其用途 | |
CN104721678A (zh) | 高良姜提取物在制备抗骨质疏松保健食品及药品方面的应用 | |
CN101066326A (zh) | 治疗肾虚的中药及其制备方法 | |
CN101244205A (zh) | 一种基于重建内稳态理论的通络降糖产品及制备方法 | |
CN101023982B (zh) | 一种治疗骨质疏松症的药物组合物 | |
CN101057940A (zh) | 中风复元丸 | |
CN1742775A (zh) | 一种预防和治疗骨科疾病的药物组合物 | |
CN102266415A (zh) | 一种复方中药在防治骨质疏松疾病中的应用 | |
CN102631595A (zh) | 治疗2型糖尿病的药物及其制备方法 | |
CN1289080C (zh) | 替代雌激素的太太天雌素及其应用 | |
CN1931280A (zh) | 治疗骨质疏松的药物及其制备方法 | |
CN103099842A (zh) | 有助于增加骨密度的软胶囊及其制备方法 | |
CN1328841A (zh) | 一种预防和治疗骨质疏松及促进骨折愈合的药物及其生产方法 | |
CN1899590A (zh) | 舒肝清热、健脾养血的妇科中成药及其制备方法 | |
CN101138597A (zh) | 一种防治骨质疏松症的中药制剂及其制备方法 | |
CN101049329A (zh) | 当归油在升高内源性雌二醇水平,用于治疗雌二醇相关性疾病的用途 | |
CN100560089C (zh) | 用于治疗骨质疏松的中药制剂 | |
CN101040889B (zh) | 一种治疗骨质疏松的中药制剂 | |
CN100484542C (zh) | 治疗骨质疏松症的中药小复方及其制备方法 | |
CN101757372B (zh) | 一种治疗骨质疏松症的组合物及其制备方法 | |
CN101385818B (zh) | 治疗黄体功能不足导致的不孕症的助孕制剂及其制备方法 | |
CN1272054C (zh) | 治疗糖尿病的药物及其制备方法 | |
CN1150921C (zh) | 一种治疗筋骨疼痛的药物及其制备方法 | |
CN1181874C (zh) | 一种治疗急性脑出血的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HEDA GENE NUTRITION CONTROL TECHNOLOGY CO Free format text: FORMER OWNER: JIANG GUREN Effective date: 20070824 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070824 Address after: 300191 Tianjin city Nankai District road rehabilitation Dan Yiyuan east side of Building 2 room 602 Patentee after: Tianjin hehe gene Nutrition Regulation Technology Co., Ltd. Address before: 300071 Tianjin City, Nankai District Wei Jin Road No. 94 southwest of the village of Nankai University 40-410 Patentee before: Jiang Guren |
|
DD01 | Delivery of document by public notice |
Addressee: Tianjin hehe gene Nutrition Regulation Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Tianjin hehe gene Nutrition Regulation Technology Co., Ltd. Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Tianjin hehe gene Nutrition Regulation Technology Co., Ltd. Document name: Notification of Termination of Patent Right |
|
DD01 | Delivery of document by public notice |
Addressee: Wei Yan Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Patent of Tianjin Heda gene Nutrition Regulation Technology Co.,Ltd. The person in charge Document name: Notice of termination of patent right |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20201111 |